Stocks · US
BMRN
XNAS
BioMarin Pharmaceuticals Inc
An overview for this page is not available in English yet. The figures below are updated daily.
Key figures 2026-10-06 basis
P/E152.64x
P/B1.76x
P/S3.27x
EPS$0.38
ROE1.15%
ROA0.62%
Dividend yield0.00%
EV/EBITDA47.30x
Debt/Equity0.66
Free cash flow$738M
Returns and 52-week range
1W-6.10%
1M-15.50%
3M-5.91%
6M+0.00%
1Y+1.43%
YTD-5.43%
52W high$70.98
52W low$49.26
From 52W high-20.79%
Company
Peers in the same sector
| Company | Market cap | P/E | P/B | 1M |
|---|---|---|---|---|
| Elanco Animal Health Incorporated Common Stock | $11.2B | — | 1.71 | -8.24% |
| 이뮤니티바이오 | $11.0B | — | — | +19.93% |
| Bio-Techne Corp. | $11.4B | 62.59 | 5.40 | +0.00% |
| Vaxcyte, Inc. Common Stock | $11.0B | — | 3.98 | +9.06% |
| DaVita Inc. | $11.4B | 13.45 | — | -1.95% |
| 쿠퍼 | $10.8B | 18.93 | 1.30 | -18.91% |
Sources and notes
This page summarizes public filings, market data and news for information only. It is not a recommendation to buy or sell any security. Figures are as of the dates shown; check the original filings before making decisions.